Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease.
Espen Thiis-EvensenAmalie Christine PooleHong-Thien Thi NguyenJon SponheimPublished in: BMC cancer (2020)
We found no treatment benefit with regard to TTP for our patients that experienced OR compared to those who achieved SD.